Our findings provide insights into the dual effects of itraconazole and posaconazole on NPC1 function and highlight the potential for optimizing new NPC1 inhibitors as pharmacological chaperones for the treatment of NPC disease. The gene discussed is NPC1; the disease is nasopharyngeal carcinoma.